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Eﬀ ectiveness of early lens extraction for the treatment of 
primary angle-closure glaucoma (EAGLE): a randomised 
controlled trial
Augusto Azuara-Blanco, Jennifer Burr, Craig Ramsay, David Cooper, Paul J Foster, David S Friedman, Graham Scotland, Mehdi Javanbakht, 
Claire Cochrane, John Norrie, for the EAGLE study group
Summary
Background Primary angle-closure glaucoma is a leading cause of irreversible blindness worldwide. In early-stage 
disease, intraocular pressure is raised without visual loss. Because the crystalline lens has a major mechanistic role, 
lens extraction might be a useful initial treatment.
Methods From Jan 8, 2009, to Dec 28, 2011, we enrolled patients from 30 hospital eye services in ﬁ ve countries. 
Randomisation was done by a web-based application. Patients were assigned to undergo clear-lens extraction or 
receive standard care with laser peripheral iridotomy and topical medical treatment. Eligible patients were aged 
50 years or older, did not have cataracts, and had newly diagnosed primary angle closure with intraocular pressure 
30 mm Hg or greater or primary angle-closure glaucoma. The co-primary endpoints were patient-reported health 
status, intraocular pressure, and incremental cost-eﬀ ectiveness ratio per quality-adjusted life-year gained 36 months 
after treatment. Analysis was by intention to treat. This study is registered, number ISRCTN44464607.
Findings Of 419 participants enrolled, 155 had primary angle closure and 263 primary angle-closure glaucoma. 
208 were assigned to clear-lens extraction and 211 to standard care, of whom 351 (84%) had complete data on health 
status and 366 (87%) on intraocular pressure. The mean health status score (0·87 [SD 0·12]), assessed with the 
European Quality of Life-5 Dimensions questionnaire, was 0·052 higher (95% CI 0·015–0·088, p=0·005) and mean 
intraocular pressure (16·6 [SD 3·5] mm Hg) 1·18 mm Hg lower (95% CI –1·99 to –0·38, p=0⋅004) after clear-lens 
extraction than after standard care. The incremental cost-eﬀ ectiveness ratio was £14 284 for initial lens extraction 
versus standard care. Irreversible loss of vision occurred in one participant who underwent clear-lens extraction and 
three who received standard care. No patients had serious adverse events.
Interpretation Clear-lens extraction showed greater eﬃ  cacy and was more cost-eﬀ ective than laser peripheral 
iridotomy, and should be considered as an option for ﬁ rst-line treatment.
Funding Medical Research Council.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
WHO ranks glaucoma as the leading cause of irreversible 
blindness,1 and prevalence is expected to increase 
substantially: compared with 20 million people who have 
primary angle-closure glaucoma now, by 2040, 34 million 
people will be aﬀ ected, of whom 5⋅3 million will be blind.2 
The prevalence of primary angle-closure glaucoma is 
highest in people of east Asian origin.2,3 Blindness is costly 
to individuals and society.4 Although most people with 
glaucoma do not become blind, many have substantially 
impaired quality of life due to restricted peripheral vision 
and the need for long-term treatment.5 Glaucoma has two 
subtypes, open angle and angle closure, in which the 
drainage pathway (trabecular meshwork at the anterior 
chamber angle) is blocked or not, respectively.6 Although 
primary open-angle glaucoma is more common, primary 
angle-closure glaucoma is more severe and more likely to 
result in irreversible blindness if not properly treated. 
Early and eﬀ ective interventions are important.
In the early stage of the disease, primary angle closure 
is accompanied by high intraocular pressure but no 
visual loss. The standard of care for primary angle closure 
and primary angle-closure glaucoma is laser peripheral 
iridotomy to open the drainage pathways and medical 
management with eye drops to reduce intraocular 
pressure.7 If the disease remains uncontrolled, surgery, 
often trabeculectomy, is indicated, which is associated 
with potentially serious complications.7
Surgical lens extraction, as used in managing 
age-related cataract, is an alternative approach for the 
management of primary angle-closure glaucoma.6,8 
Age-related growth of the lens plays a major part in the 
mechanisms leading to primary angle-closure glaucoma, 
and lens extraction is used routinely in patients with 
coexisting cataract. However, the eﬃ  cacy and safety of 
this treatment in people with primary angle-closure 
glaucoma without cataract has not been fully assessed.9 If 
lens extraction could control the condition, the need for 
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medications and subsequent glaucoma surgery should 
be reduced. Furthermore, clear-lens extraction could help 
to maintain good visual acuity and improve quality of life 
by correcting hypermetropic refractive error, which 
frequently aﬀ ects these patients, and reduce the need for 
wearing spectacles.10 Weighing against initial clear-lens 
extraction, though, are the potential risks of severe 
complications associated with intraocular surgery.
We did a multicentre, randomised, controlled trial to 
assess the eﬃ  cacy, safety, and cost-eﬀ ectiveness of 
clear-lens extraction compared with laser peripheral 
iridotomy and topical medical treatment as ﬁ rst-line 
therapy in people with newly diagnosed primary angle 
closure with raised intraocular pressure or primary 
angle-closure glaucoma (ie, those at the highest risk of 
visual loss). We tested the hypothesis that initial clear-
lens extraction would be associated with better quality of 
life, lower intraocular pressure, and less need for 
glaucoma surgery at 36 months than standard care. 
The protocol of the study has been published.11
Methods
Study design and participants
We did this multicentre, comparative eﬀ ectiveness, 
randomised, controlled trial in 30 hospital eye services in 
ﬁ ve countries: Australia (one hospital), mainland China 
(one), Hong Kong (two), Malaysia (two), Singapore (two), 
and the UK (22).
We recruited patients who were phakic, aged 50 years or 
older (to limit the eﬀ ect of loss of accommodation 
associated with clear-lens extraction), and had newly 
diagnosed primary angle closure with intraocular pressure 
30 mm Hg or greater or primary angle-closure glaucoma. 
Primary angle closure was deﬁ ned as iridotrabecular 
contact, either appositional or synechial, of at least 180° 
on gonioscopy, and primary angle-closure glaucoma 
as reproducible glaucomatous visual ﬁ eld defects, 
glaucomatous optic neuropathy, or both, and intraocular 
pressure greater than 21 mm Hg on at least one occasion. 
Patients with symptomatic cataract, advanced glaucoma 
(mean deviation worse than –15 dB or cup-to-disc ratio 
≥0·9), or previous acute angle-closure attack or who had 
undergone previous laser or ocular surgery were excluded. 
An ophthalmologist identiﬁ ed eligible patients and those 
informed about the study were noted in a log book. People 
willing to participate completed clinical measurements 
and study questionnaires at baseline.
The study adhered to the tenets of the Declaration of 
Helsinki and was approved by local institutional review 
boards. Study participants provided written informed 
consent. An independent data monitoring committee 
and an independent trial steering committee provided 
oversight.
Randomisation and masking
The randomisation schedule was created with a web-based 
application at the Centre for Healthcare Randomised Trials, 
University of Aberdeen, Aberdeen, UK. The randomisation 
algorithm used sex, centre, ethnic origin (Chinese or 
non-Chinese), diagnosis, and one or both eyes suitable 
for treatment as minimisation covariates.12 Outcomes 
assessors were masked when possible, as described later. 
Patients were assigned in equal proportions to treatment 
with clear-lens extraction or laser peripheral iridotomy and 
topical medical treatment (standard care). Enrolment and 
randomisation was done by the local ophthalmologists.
Procedures
Topical medications started at the time of diagnosis were 
continued and the interventions were performed within 
60 days of randomisation. If both of a patient’s eyes were 
suitable for treatment, they were treated in the same way 
but data for the eye with more severe disease was used in 
the analysis of eye-level outcomes. If only one eye was 
suitable for treatment, the other was managed according 
to the clinical judgment of the ophthalmologist.
 Research in context
Evidence before this study
We identiﬁ ed a Cochrane systematic review that had not found any 
relevant randomised controlled trials. We also searched the 
National Research Register, Current Controlled Trials, 
ClinicalTrials.gov, the WHO International Clinical Trial Registry, 
MEDLINE, Embase, the Science Citation Index, Biosis, CENTRAL, 
and Scopus In Press with the following terms: “glaucoma”, “angle-
closure”, “PACG”, “phacoemulsiﬁ cation”, “lens extraction”, and 
“lens removal” for papers published from inception until June 30, 
2007. We updated our searches during the trial, with the last being 
done in January, 2016. We found no trials assessing early (clear) 
lens extraction as the primary treatment for chronic primary 
angle-closure glaucoma. We identiﬁ ed clinical trials that had 
assessed interventions for primary angle-closure glaucoma, but 
they studied diﬀ erent populations (eg, patients with cataract or 
after acute attacks of angle closure), lens extraction after other 
treatments had failed to control the disease, or both.
Added value of this study
This large multicentre randomised controlled trial provides 
evidence supporting the use of initial clear-lens extraction as a 
ﬁ rst-line intervention for primary angle-closure glaucoma and 
primary angle closure with high intraocular pressure.
Implications of all the available evidence
Laser peripheral iridotomy as the initial treatment for 
angle-closure glaucoma should be reconsidered. This study 
provides robust evidence that initial clear-lens extraction is 
associated with better clinical and patient-reported outcomes, 
and that this approach is likely to be cost-eﬀ ective in a publicly 
funded health system.
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Participants assigned to clear-lens extraction underwent 
phacoemulsiﬁ cation with a monofocal intraocular lens 
implant. Temporary treatment with eye drops was 
allowed while patients were awaiting surgery. 
Synechiolysis was allowed according to local practice. 
Fully qualiﬁ ed ophthalmologists who had completed 
general training in ophthalmology and specialist training 
in glaucoma did the surgeries. Laser iridoplasty was 
allowed after standard care if angle closure persisted.
A target intraocular pressure of 15–20 mm Hg was set at 
baseline dependent on the degree of optic nerve damage. 
Topical medical therapy could be escalated (ie, by increasing 
the number of medications) to achieve this target. If 
maximum medical therapy did not control the intraocular 
pressure, the ophthalmologist could oﬀ er and choose the 
type of glaucoma surgery. The need for glaucoma surgery 
was classiﬁ ed as a treatment failure, but participants 
remained in the trial. Patients assigned to standard care 
could undergo lens extraction during the study period only 
when indicated clinically for reduced vision (ie, cataract 
surgery) or if the treating ophthalmologist judged that lens 
extraction could help control the intraocular pressure.
Assessments
We measured health status with the European Quality 
of Life-5 Dimensions (EQ-5D) questionnaire, which 
assesses ﬁ ve dimensions of health (mobility, self-care, 
usual activity, pain or discomfort, and anxiety or 
depression) at three levels (no problems, some problems, 
extreme problems).13,14 Each of the 243 health states that 
may be described by the instrument can be assigned a 
single preference-based utility score, which we calculated 
with the UK general population tariﬀ  for time trade-oﬀ .15 
The questionnaires were self-reported by patients, who 
were aware of treatment allocation.
Intraocular pressure was taken to be the average of two 
readings by Goldmann tonometry. Two observers at each 
site, following a masking protocol, were involved in the 
measurements. One observer randomly set the starting 
force and recorded the pressure values obtained by the 
other observer, who interacted directly with the patient but 
did not look at the results on the measurement dial. 
Outcomes were assessed at baseline and 6, 12, 24, and 
36 months after randomisation.
We captured data on use of UK National Health Service 
(NHS) resources with the use of case report forms. 
Results of all eye procedures and outpatient follow-up 
assessments and use of all medications for UK patients 
were recorded and patients were asked to complete 
questionnaires during primary care, community nurse, 
and optometrist visits. The results were combined with 
national unit cost data for the ﬁ nancial year 2012–13 to 
estimate total costs per participant to 36 months.16–18 
Total quality-adjusted life-years (QALYs) were calculated 
for each participant on the basis of their EQ-5D utility 
scores at baseline and at 6, 12, 24, and 36 months, and 
we assumed that change in health state use between 
time points would be linear. Full details of the economic 
analysis and modelling to extrapolate cost-eﬀ ectiveness 
over longer time periods will be published elsewhere.
To assess the eﬀ ects of vision problems on vision-targeted 
functioning and health-related quality of life, we used the 
National Eye Institute Visual Function Questionnaire-25 
(NEI-VFQ-25).19,20 This questionnaire has 11 subscales and 
one general health rating question, from which a composite 
score is generated. Additionally, we used the Glaucoma 
Utility Index, which provides a descriptive proﬁ le in 
six dimensions: central and near vision, lighting and glare, 
mobility, activities of daily living, eye discomfort, and other 
eﬀ ects of glaucoma and its treatment, each with four levels.21
Best-corrected visual acuity was tested with the Early 
Treatment Diabetic Retinopathy Study (ETDRS) charts22 
and extension of angle closure was determined by 
gonioscopy. To test the visual ﬁ eld, we used a standard 
automated perimetry test (Humphrey SITA 24-2 test). 
Participants did two tests at baseline and one at 6, 12, 24, 
and 36 months. Individual disease progression was 
deﬁ ned as a worsening of one or more stages according 
to the Glaucoma Staging System-2,23 and was decided by 
graders unaware of participants’ treatment allocations. 
Visual ﬁ eld tests were deemed to be unreliable when 
false-positive errors were greater than 15%.
Safety
Any expected or unexpected complications during 
treatment or at any time during follow-up were recorded 
on case-report forms and submitted to the data monitoring 
committee, including loss of best-corrected visual acuity of 
more than ten ETDRS letters. Serious adverse events were 
805 patients assessed
for eligibility
386 patients ineligible or 
chose not to participate
419 enrolled
419 randomised
208 assigned to clear-lens 
extraction
4 patients data not
 available
204 included in the 
intention-to-treat 
analysis
211 assigned to laser 
peripheral iridotomy
6 patients data not
 available
205 included in the 
intention-to-treat 
analysis
Figure 1: Trial proﬁ le
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reported in accordance with the guidance from the 
National Research Ethics Service, which is a subdivision of 
the National Patient Safety Agency.
Statistical analysis
We calculated that with 170 participants in each group, 
the study would have 90% power at 5% signiﬁ cance level 
to detect a diﬀ erence in mean EQ-5D score of 0·35 SD, 
which represents an absolute change in score of 0·0520 
and is likely to be clinically important. We estimated that 
the SD for intraocular pressure at 36 months would be 
5 mm Hg and similar in the two randomised groups.24–26 
We therefore calculated that the study would have 90% 
power at a 5% level of signiﬁ cance to detect a mean 
diﬀ erence of 1·75 mm Hg. Additionally, with the 
assumption that a maximum of 40% of patients would 
need glaucoma surgery, the power to detect a diﬀ erence 
of 15% in the need for glaucoma surgery would be 80%. 
Thus, allowing for 15% loss to follow-up at 36 months, 
we aimed to recruit 400 patients.
All the main analyses were based on intention to treat 
(ITT) and were done at the end of the trial. Signiﬁ cance 
was set at 5% in the main analysis and 1% in the 
subgroup analyses. To assess the primary outcomes, we 
used a repeated measures mixed eﬀ ects model to analyse 
the EQ-5D scores and intraocular pressure,27 based on 
the follow-up data obtained at 6, 12, 24, and 36 months. 
Participants with observations from at least one of these 
timepoints were included in the analyses. Baseline 
EQ-5D scores and intraocular pressure values were used 
as explanatory variables. The model included ﬁ xed eﬀ ects 
for sex, ethnic origin, diagnosis, whether glaucoma was 
present in one or both eyes, and intervention. Dummy 
variables for the timepoint were included to enable 
investigation of the eﬀ ects of the interventions at each 
timepoint. Random eﬀ ects were included for centre and 
individual. The model was extended for subgroup 
analyses by ﬁ tting a dummy variable for each respective 
subgroup. These dummy variables were used to create 
further interaction terms to represent the eﬀ ect of clear-
lens extraction in the subgroups at each of the timepoints, 
expressed as odds ratios and 95% CIs. 
The secondary continuous and binary outcomes were 
analysed with appropriate generalised linear models. 
The unit of analysis for the clinical outcomes was the 
treated eye (the worse eye if both were suitable for 
treatment). For quality of life measures, the unit of 
analysis was the participant, with bilateral disease 
included as a ﬁ xed eﬀ ect covariate. To account for 
missing answers in questionnaires we followed the 
authors’ recommendations. These allow a score to be 
generated if there are missing questions in the 
NEI-VFQ-25, whereas for EQ-5D and the glaucoma-
speciﬁ c disability questionnaire, no score is assigned.
Planned subgroup analyses used the minimisation 
variables ethnic origin (Chinese or non-Chinese), 
diagnosis (primary angle closure or primary angle-closure 
glaucoma), and unilateral or bilateral disease. We added 
an unplanned subgroup analysis after baseline visual 
acuity data were assessed to explore the possible diﬀ erence 
in the primary outcome between patients with excellent 
and slightly decreased visual acuity (≥85 ETDRS letters vs 
<85 ETDRS letters).
The in-trial cost-eﬀ ectiveness data were obtained with 
seemingly unrelated regression adjustment for baseline 
cost and EQ-5D score. We compared mean costs and 
eﬀ ects to estimate the incremental cost-eﬀ ectiveness ratio 
(ICER) for clear-lens extraction versus standard care. 
Clear-lens extraction 
(n=208)
Laser peripheral 
iridotomy (n=211)
Missing data
Demographics
Women 122 (59%) 121 (57%) 0
Chinese origin 62 (30%) 66 (31%) 0
Age (years) 67·0 (61·0–73·0) 67·0 (61·0–73·0) 0
Ocular characteristics and treatments
Both eyes suitable for treatment 76 (37%) 76 (36%) 0
Study eye was right eye 110 (53%) 118 (56%) 0
Diagnosis in study eye
PAC 80 (38%) 75 (36%) 0
PACG 127 (61%) 136 (64%) 0
Missing 1 (0%)
Systemic warfarin use 11 (5%) 7 (3%) 1
Systemic α-agonist use 17 (8%) 25 (12%) 0
Glaucoma topical medication
None 83 (40%) 79 (37%) 0
One 71 (34%) 79 (37%) 0
Two 35 (17%) 37 (18%) 0
Three 16 (8%) 10 (5%) 0
Four 2 (1%) 5 (2%) 0
Five 1 (0%) 1 (0%) 0
Glaucoma oral medication 0 2 (1%) 0
IOP (mm Hg) 30·0 (24·0 to 33·0) 30·0 (26·0 to 33·0) 0
Axial length (mm) 22·5 (22·0 to 23·1) 22·7 (22·1 to 23·2) 7
Anterior chamber depth (mm) 2·5 (2·3 to 2·7) 2·5 (2·3 to 2·7) 17
Refractive error (dioptres) 1·6 (0·5 to 3·0) 1·1 (0·0 to 2·4) 39
Visual ﬁ eld mean deviation (dB) –3·0 (–7·0 to –0·8) –3·5 (–7·2 to –1·3) 42
Central corneal thickness (μm) 553·0 (528·0 to 576·0) 551·0 (522·0 to 582·0) 5
Gonioscopy (angle closure º)
Closure without indentation 300·0 (270·0 to 360·0) 360·0 (270·0 to 360·0) 23
Synechial closure 90·0 (20·0 to 180·0) 90·0 (10·0 to 180·0) 247
BCVA, ETDRS (N letters) 80·0 (74·0 to 85·0) 79·0 (71·0 to 85·0) 7
Binocular BCVA, ETDRS 85·0 (79·0 to 88·0) 84·0 (79·0 to 88·0) 17
Patient-reported instrument scores
NEI-VFQ-25 90·9 (83·6 to 95·5) 90·3 (83·3 to 95·9) 6
EQ-5D 1·000 (0·796 to 1·000) 1·000 (0·796 to 1·000) 11
Glaucoma Utility Index 0·897 (0·791 to 0·991) 0·921 (0·791 to 1·000) 17
Data are number (%) or median (IQR). PAC=primary angle closure. PACG=primary angle-closure glaucoma. 
IOP=intraocular pressure. MD=mean deviation index. BCVA=best-corrected visual acuity. ETDRS=Early Treatment 
Diabetic Retinopathy Study. NEI-VFQ–25=National Eye Institute Visual Function Questionnaire-25. EQ-5D=European 
Quality of Life-5 Dimensions questionnaire.
Table 1: Baseline characteristics 
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Non-parametric bootstrapping was used to generate 
95% CIs for the estimated diﬀ erences in mean costs and 
QALYs, and to ascertain the probability of the ICER for the 
clear-lens extraction approach being cost-eﬀ ective at 
diﬀ erent ceiling ratios. In accordance with the guidance of 
the National Institute for Health and Care Excellence,28 we 
report these probabilities at ceiling ratios of £20 000 and 
£30 000 per QALY gained to represent decision makers’ 
maximum willingness to pay per QALY gained. All 
analyses were also repeated with a multiple imputation 
dataset (n=20) generated with the use of chained equations 
to deal with missing cost and utility data.29 Analyses were 
done with Stata version 12. This study is registered with 
the ISRCTN registry, number ISRCTN44464607.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results 
Of 805 patients assessed, 250 did not meet the inclusion 
criteria and 136 declined to participate, meaning that 
419 individuals were recruited between Jan 8, 2009, and 
Dec 28, 2011. 208 were assigned to undergo clear-lens 
extraction and 211 to receive standard care (ﬁ gure 1). 
155 (37%) participants had primary angle closure and 
263 (67%) had primary angle-closure glaucoma. 128 (31%) 
participants were of Chinese and 291 (69%) were of 
non-Chinese ethnicity. In 152 (36%) participants both 
eyes were suitable for treatment. One participant 
randomly assigned to clear-lens extraction was classiﬁ ed 
as a crossover. 409 (98%) of patients were included in the 
intention-to-treat analysis (ﬁ gure 1), with the ﬁ nal visit 
being held in December, 2014. Baseline characteristics 
were similar in the two treatment groups (table 1). Among 
participants who underwent clear-lens extraction, 18 (9%) 
had viscosynechiolysis associated with the surgical 
procedure. In the standard care group, ten (5%) underwent 
laser iridoplasty.
EQ-5D scores and intraocular pressure at 36 months 
signiﬁ cantly favoured the clear-lens extraction group 
(table 2). The economic analysis was based on 179 of 
285 participants recruited in UK centres for whom 
complete cost and QALY data were available. Of these, 
93 were assigned to undergo clear-lens extraction and 
86 to receive standard care. Mean adjusted NHS costs 
were higher with initial clear-lens extraction than with 
standard care (£2467 vs £1486), resulting in a mean 
incremental cost of £981 (95% CI 612–1317). The 
corresponding mean QALYs were also higher in the 
clear-lens extraction group (2⋅602 vs 2⋅533), resulting in 
a mean incremental QALY gain of 0⋅069 (–0⋅017 to 
0⋅159). The ICER, therefore, was £14 284 per QALY 
gained for clear-lens extraction versus standard care. At 
the ceiling ratios of £20 000 and £30 000 per QALY 
gained, the probabilities of cost-eﬀ ectiveness were 0⋅671 
and 0⋅776, respectively. The analysis based on multiple 
imputation data gave an estimated incremental cost of 
£844 (95% CI 551–1124) for initial clear-lens extraction 
(£2411 vs £1567 for standard care), for an incremental 
QALY gain of 0⋅100 (2⋅542 vs 2⋅442, 95% CI 0⋅016–0⋅193). 
The estimated ICER after this analysis was £8430, and 
the probability of clear-lens extraction being cost-eﬀ ective 
was 0⋅885 at a ceiling ratio of £20 000 per QALY and 
0⋅940 at the ceiling ratio of £30 000 per QALY.
NEI-VFQ-25 and Glaucoma Utility Index scores at 
36 months were signiﬁ cantly higher in the clear-lens 
extraction group than in the standard care group (both 
p<0·0001, table 3). Signiﬁ cantly fewer participants in the 
clear-lens extraction group needed any treatment to control 
intraocular pressure (p<0·0001) and fewer needed 
glaucoma medications than patients who received standard 
care (table 3). The most common type of medication used 
was prostaglandin analogue (41 [20%] patients in the clear-
lens extraction group and 105 [50%] in the standard care 
group) then β blockers (14 [7%] and 54 [26%]). Degrees of 
appositional and synechial angle closure were not reported 
in most participants, but the available data suggest that 
neither diﬀ ered signiﬁ cantly between groups (odds ratio 
0·78, 95% CI 0·187–3·250 and 0·565, 0·257–1·242, 
respectively). Visual ﬁ eld severity at 36 months was similar 
in the two treatment groups (table 3) and had worsened in 
24 participants in the clear-lens extraction group and 
30 individuals in the laser iridotomy group (odds ratio 0·77, 
95% CI 0·392–1·511).
There were no serious adverse events (table 4). 75 patients 
(25 in the clear-lens extraction group and 50 in the standard 
care group) had at least one complication. Posterior 
Clear-lens extraction 
(n=208)
Laser peripheral 
iridotomy (n=211)
Diﬀ erence in change 
between groups (95% CI)
p value
European Quality of Life-5 Dimensions questionnaire
Baseline 204, 0·867 (0·186) 204, 0·876 (0·178) ·· ··
6 months 182, 0·894 (0·181) 191, 0·846 (0·218) ·· ··
12 months 185, 0·899 (0·152) 184, 0·859 (0·204) ·· ··
24 months 175, 0·883 (0·179) 179, 0·856 (0·216) ·· ··
36 months 176, 0·870 (0·213) 175, 0·838 (0·234) ·· ··
Baseline vs 
36 months
·· ·· 0·052 (0·015 to 0·088) 0·005
Intraocular pressure (mm Hg)
Baseline 208, 29·5 (8·2) 211, 30·3 (8·1) ·· ··
6 months 195, 15·7 (4·3) 202, 19·2 (5·2) ·· ··
12 months 192, 15·9 (3·2) 195, 18·4 (4·3) ·· ··
24 months 186, 17·0 (3·9) 183, 18·8 (4·6) ·· ··
36 months 182, 16·6 (3·5) 184, 17·9 (4·1) ·· ··
Baseline vs 
36 months
·· ·· –1·18 (–1·99 to –0·38) 0·004
Data for groups are number of patients with mean (SD).
Table 2: Patient-reported and clinical primary endpoints 
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capsule rupture was seen after two clear-lens extractions 
(1%). No severe complications were reported as a direct 
consequence of laser iridotomy. Irreversible loss of vision 
of more than ten ETDRS letters was seen in one participant 
in the clear-lens extraction group and three in the standard 
care group. Intolerance of medications was reported less 
frequently in the clear-lens extraction group than in the 
standard group (three vs ten participants, diﬀ erence 3·3%, 
95% CI 0·004–6·6, p=0·049). Further intraocular surgery 
was needed to manage complications of the primary or 
additional interventions in three patients (zonulo-
hyaloido-vitrectomy for malignant glaucoma, repositioning 
of a subluxated intraocular lens, and injection of antibody 
against VEGF for macular oedema) in the clear-lens 
extraction group and one participant (pars plana vitrectomy 
for dislocated lens) in the standard care group. Also in the 
latter group, 12 (6%) patients underwent surgery for 
clinically relevant cataracts. One patient in the clear-lens 
extraction group developed transient corneal oedema and 
another suﬀ ered malignant glaucoma. Central corneal 
thickness did not diﬀ er between groups. One patient in the 
clear-lens extraction group developed an acute angle-
closure attack before the operation and was treated with 
laser peripheral iridotomy (crossover).
Regarding subgroup analyses, no eﬀ ect was seen on 
the primary outcomes of EQ-5D score and intraocular 
pressure (ﬁ gure 2).
Discussion
In this multicentre international randomised controlled 
trial, initial treatment with clear-lens extraction was 
superior to laser peripheral iridotomy plus topical 
medical treatment for participants with primary 
angle closure and primary angle-closure glaucoma. 
The relevance of the changes reported by patients is hard 
to quantify, but overall health status, visual impairment 
and disability, and glaucoma-speciﬁ c disability were all 
improved even though the patients did not have cataracts. 
Multiple factors probably contributed to the diﬀ erences 
between groups in the patient-related outcomes, 
including reduced need for glaucoma medications and 
surgery after intervention, improvement of visual 
function (eg, contrast sensitivity) after eliminating mild 
age-related changes in lens transparency, and by 
correction of refractive error, which resulted in good 
visual acuity without the need for spectacles. Visual 
acuity was better in the clear-lens extraction group than 
in the standard care group by three ETDRS letters. While 
this magnitude of change is unlikely to be clinically 
important, it points to the overall improvement in visual 
function associated with clear-lens extraction.
Intraocular pressure was better with clear-lens 
extraction than with standard care, with the mean 
pressure being around 1 mm Hg lower in the clear-lens 
extraction group at 3 years. Although this diﬀ erence is 
small and by itself is unlikely to be clinically relevant, 
only 21% of participants in the clear-lens extraction group 
Clear-lens extraction 
(n=208)
Laser peripheral 
iridotomy (n=211)
Diﬀ erence in change 
between groups (95% CI)
p value
Patient-reported NEI-VFQ-25
Baseline 206, 86·8 (12·4) 207, 87·4 (12·1) ·· ··
6 months 187, 89·6 (10·0) 196, 87·3 (12·5) ·· ··
12 months 188, 90·7 (9·8) 188, 86·9 (13·1) ·· ··
24 months 177, 90·0 (10·6) 183, 85·7 (13·5) ·· ··
36 months 185, 90·1 (12·3) 180, 85·1 (16·2) ·· ··
36 months vs 
baseline
·· ·· 5·33 (3·36 to 7·30) <0·0001
Glaucoma Utility Index
Baseline 203, 0·855 (0·151) 199, 0·865 (0·161) ·· ··
6 months 182, 0·901 (0·117) 194, 0·869 (0·147) ·· ··
12 months 184, 0·897 (0·111) 182, 0·868 (0·130) ·· ··
24 months 171, 0·893 (0·117) 182, 0·860 (0·142) ·· ··
36 months 180, 0·899 (0·132) 178, 0·843 (0·173) ·· ··
36 months vs 
baseline
·· ·· 0·061 (0·038 to 0·085) <0·0001
Medications (eye drops)
Baseline 204, 1·0 (1·0) 209, 1·0 (1·0) ·· ··
6 months 192, 0·4 (0·7) 200, 1·0 (0·9) ·· ··
12 months 186, 0·3 (0·6) 193, 1·1 (0·9) ·· ··
24 months 177, 0·4 (0·8) 180, 1·2 (1·0) ·· ··
36 months 178, 0·4 (0·8) 181, 1·3 (1·0) ·· ··
36 months vs 
baseline
·· ·· 0·338 (0·264 to 0·432) <0·0001
Medications (any) at 36 months*
0 126 (60·6%) 45 (21·3%) ·· ··
1 33 (15·9%) 67 (31·8%) ·· ··
2 15 (7·2%) 46 (21·8%) ·· ··
3 3 (1·4%) 19 (9·0%) ·· ··
4 1 (0·5%) 4 (1·9%) ·· ··
Missing 30 (14·4%) 30 (14·2%) ·· ··
Additional glaucoma surgery†
Lens extraction 0 16 (67%) of 24 ·· ··
Trabeculectomy 1 (100%) of 1 6 (25%) of 24 ·· ··
i-Stent 0 1 (4%) of 24 ·· ··
Ahmed tube 0 1 (4%) of 24 ·· ··
Angle closure at 36 months (°)
0–180 44 (21·2%) 41 (19·4%) ·· ··
181–360 17 (23·6%) 37 (34·6%) ·· ··
Missing 136 (65·4%) 104 (49·3%) ·· ··
36 months vs 
baseline
·· ·· 0·565 (0·257 to 1·242) 0·156
Synechial angle closure at 36 months (°)
0–180 76 (89·4%) 68 (86·1%) ·· ··
181–360 9 (10·6%) 11 (13·9%) ·· ··
Missing 123 (59·1%) 132 (62·6%) ·· ··
36 months vs 
baseline
·· ·· 0·780 (0·187–3·250) 0·733
Visual ﬁ eld MD (dB)
Baseline 196, –5·1 (5·3) 198, –5·4 (5·8) ·· ··
6 months 169, –4·1 (5·0) 176, –4·8 (6·1) ·· ··
12 months 182, –4·3 (5·2) 184, –4·8 (6·1) ·· ··
(Table 3 continues on next page)
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received any further treatment to control intraocular 
pressure, compared with 61% who received at least one 
glaucoma drop in the laser peripheral iridotomy group. 
The study protocol stipulated a target intraocular 
pressure and allowed clinicians to escalate treatment if 
and when needed to achieve this. Thus, large diﬀ erences 
in mean intraocular pressure were not expected.
The superior clinical eﬃ  cacy of initial clear-lens 
extraction is supported by the reduced need for further 
glaucoma surgery in this group than in the standard care 
group (one vs 24 operations). The resulting reduction in 
intraocular pressure associated with the glaucoma 
surgery probably blunted the diﬀ erence in the eﬃ  cacy of 
lowering of intraocular pressure between the two treat-
ment groups. A small proportion of patients assigned 
standard care had cataract surgery for vision complaints 
and might also have beneﬁ ted from lowering of 
intraocular pressure after this surgery.
Glaucoma severity, as measured with visual ﬁ eld 
testing, did not diﬀ er between the two groups, but the 
study was not powered speciﬁ cally to detect this 
diﬀ erence. The number of individuals with deterioration 
in visual ﬁ eld (24 individuals in the clear-lens extraction 
group and 31 participants in the standard care group) 
also did not diﬀ er signiﬁ cantly (odds ratio 0·77, 
95% CI 0·38–1·55).
Outcomes did not diﬀ er when assessed in any of the 
subgroups. We excluded patients with severe primary 
angle-close glaucoma and, therefore, our ﬁ ndings might 
not be applicable to patients with advanced disease. 
Similarly, we only included patients with primary angle 
closure if intraocular pressure was high. Whether 
patients with primary angle closure and intraocular 
pressure less than 30 mm Hg would beneﬁ t equally from 
clear-lens extraction is, therefore, unclear. We added a 
subgroup analysis of the eﬀ ect of excellent versus slightly 
decreased visual acuity, but found no diﬀ erence between 
groups (ﬁ gure 2).
Clear-lens extraction might be associated with severe 
intraoperative and postoperative complications.7,30 Two 
participants had posterior capsule rupture, which is a 
known complication of clear-lens extraction surgery and 
is associated with increased risk of poor visual outcomes. 
However, the frequency of this complication was low and 
was similar to that in large series of cataract surgery.30 
One participant developed malignant glaucoma and 
another transient corneal oedema. The net eﬀ ect of these 
surgical complications was small because the number of 
participants with irreversible loss of vision of more than 
ten ETDRS letters was similar in the two treatment 
groups; however, the risk of severe complications after 
clear-lens extraction must be taken into account from the 
perspective of individual patients. The low frequency of 
complications associated with clear-lens extraction might 
have been related to the skills of the treating surgeons, 
who had completed general and specialist training in 
ophthalmology and glaucoma, and might not be similar 
Clear-lens extraction 
(n=208)
Laser peripheral 
iridotomy (n=211)
Diﬀ erence in change 
between groups (95% CI)
p value
(Continued from previous page)
24 months 173, –4·4 (5·3) 172, –5·2 (6·5) ·· ··
36 months 172, –4·7 (5·5) 172, –5·0 (6·4) ·· ··
Baseline vs 36 
months
·· ·· 0·08 (–0.59 to 0.75) 0·814
Central corneal thickness (μm)*
Baseline 207, 551·5 (37·9) 207, 551·9 (39·2) ·· ··
36 months 171, 551·5 (39·6) 164, 543·2 (38·4) ·· ··
Refractive error (dioptres)*
Baseline 189, 1·7 (2·3) 191, 1·2 (2·3) ·· ··
36 months 168, 0·08 (0·95) 172, 0·92 (2·18) ·· ··
Visual acuity (ETDRS letters)
Baseline 207, 77·9 (12·4) 205, 77·0 (12·6) ·· ··
12 months 183, 81·6 (9·3) 192, 79·0 (11·2) ·· ··
36 months 176, 79·9 (10·9) 179, 76·6 (14·8) ·· ··
Baseline vs 36 
months
·· ·· 2·99 (0·99 to 5·00) 0·003
Data are number of patients with mean (SD) or number of patients (%). NEI-VFQ-25=National Eye Institute Visual 
Function Questionnaire-25. MD=Mean Deviation index. ETDRS=Early Treatment Diabetic Retinopathy Study chart. 
*Not done because not part of the planned statistical analysis. †Difference in numbers of additional surgeries between 
groups was –10·9% (–15·3 to –6.5), p<0·0001.
Table 3: Patient-reported and clinical secondary endpoints 
Clear-lens 
extraction (n=208)
Laser peripheral 
iridotomy (n=211)
Intraoperative  
Posterior capsule rupture 2 (1·0%) 0
Iris prolapse 2 (1·0%) 0
Vitreous loss 1 (0·5%) 0
Broken haptic 1 (0·5%) 0
Bleeding or haemorrhage 0 16 (7·6%)
Postoperative 
Flat anterior chamber 2 (1·0%) 1 (0·5%)
Retinal detachment or tear 0 1 (0·5%)
Malignant glaucoma 1 (0·5%) 2 (1·0%)
Corneal oedema 1 (0·5%)
Macular oedema 5 (2·4%) 3 (1·4%)
Spike in intraocular pressure 2 (1·0%) 5 (2·4%)
Postoperative inﬂ ammation 5 (2·4%) 1 (0·5%)
Central retinal vein occlusion 0 1 (0·5%)
Dysphotopsia 0 1 (0·5%)
Posterior vitreous detachment 0 1 (0·5%)
Macular hole 1 (0·5%) 0
Systemic event (unrelated) resulting in hospital admission 2 (1·0%) 0
Intraocular surgery required for complications 3 (1·4%) 1 (0·5%)
Irreversible loss of >10 ETDRS letters 1 (0·5%) 3 (1·4%)
Irritation from eye drops 0 1 (0·5%)
Intolerance to medication 3 (1·4%) 10 (4·7%)*
Lens extraction for cataract NA 12
ETDRS=Early Treatment Diabetic Retinopathy Study chart. NA=not applicable. *p=0·049. 
Table 4: Adverse events 
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if surgery were performed by less experienced surgeons. 
The number of participants needing further surgery to 
manage complications at any timepoint was similar in 
the two groups. Furthermore, 12 individuals originally 
assigned to laser peripheral iridotomy needed cataract 
surgery for visual reasons, which suggests that many 
people treated with this approach will be at risk of future 
cataract extraction. The lack of diﬀ erence between groups 
for central corneal thickness also supported the relative 
safety of clear-lens extraction as ﬁ rst-line treatment.
Within-trial cost-eﬀ ectiveness data showed that 
clear-lens extraction was associated with increased mean 
cost to the NHS and increased mean QALYs at 3 years. At 
a ceiling willingness-to-pay ratio of £20 000 per QALY 
gained, the probability of early clear-lens extraction being 
cost-eﬀ ective is 67% based on complete case data, or 
89% based on the multiple imputation analysis. The latter 
analysis suggested that patients with missing economic 
data were predicted to have poorer outcomes for quality 
of life than those with complete data, particularly in the 
standard care group (as well as higher costs in this group), 
leading to a slightly more favourable ICER for early clear-
lens extraction. The incremental cost associated with 
early clear-lens extraction is driven by increased initial 
procedure costs (£1229 vs £181), but these are partly oﬀ set 
over follow-up by cost savings associated with reduced 
need for subsequent procedures and medications. The 
cost-eﬀ ectiveness of clear-lens extraction might, therefore, 
improve further in the long term if this trend continues.
This trial has several strengths, including its pragmatic 
design, the large sample with low attrition, the involvement 
of centres in the UK and Asia, the randomisation process, 
and masking of the clinical assessments of intraocular 
pressure, visual acuity, and visual ﬁ elds, which kept the 
potential risk of bias to a minimum. This study also had 
some limitations. The surgical treatments could not be 
masked from participants, nor could the clinical outcome 
assessments for gonioscopy or complications. A large 
proportion of gonioscopic data was not reported. 
Deﬁ nitions of complications, such as inﬂ ammation and 
spikes in intraocular pressure, were not standardised. 
There might have been a diﬀ erence between Chinese and 
non-Chinese populations that we did not detect and, 
therefore, the generalisability of our results to Asian 
populations should be explored further.
Although one good-quality trial might not be enough to 
change policy, the consistent superiority of clear-lens 
extraction in terms of patient-reported and clinical beneﬁ ts 
and the absence of serious safety issues provide strong 
support for considering this approach as the ﬁ rst-line 
treatment for individuals with primary angle-closure 
disease. The results are consistent with those in previously 
published case series. Longer-term follow-up of visual 
function and visual ﬁ eld progression could be useful, 
owing to the slow progression of this disease when treated. 
Overall, our results indicate that clear-lens extraction 
should be considered the initial treatment for primary 
angle-closure glaucoma and primary angle closure with 
increased intraocular pressure.
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Figure 2: Mean diﬀ erences in subgroup outcomes between clear-lens extraction and standard care
(A) Quality of life scores on the European Quality of Life-5 Dimensions questionnaire. (B) Intraocular pressure. Red dotted vertical line indicates overall diﬀ erence between 
clear-lens extraction and standard care. PAC=primary angle closure. PACG=primary angle-closure glaucoma. ETDRS=Early Treatment Diabetic Retinopathy Study chart. 
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